AI Article Synopsis
- The study aimed to evaluate how effective tumor necrosis factor-alpha inhibitors (TNFi) are for treating uveitic macular edema (ME) that doesn't respond to traditional medications (csDMARDs).
- Researchers conducted a retrospective analysis on 35 eyes of 26 patients over 4 years, measuring changes in central retinal thickness (CRT), visual acuity, and the need for corticosteroids.
- Results showed a significant decrease in CRT and improvement in visual acuity, plus a reduction in patients needing corticosteroids, indicating that TNFi can be beneficial for managing uveitic ME over the long term, although some patients still required additional treatments.
Article Abstract
Purpose: To assess the efficacy of tumor necrosis factor-alpha inhibitors (TNFi) on uveitic macular edema (ME) unresponsive to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).
Methods: This multicenter retrospective study included patients with uveitic ME persisting despite csDMARDs. The effect of an additional TNFi on central retinal thickness (CRT), best corrected visual acuity (BCVA) and corticosteroid need was evaluated.
Results: Thirty-five eyes (26 patients, mean age 42.9 ± 15.2 years) were included. CRT decreased from 425 ± 137 µm to 294 ± 66 µm ( < .001) and 280 ± 48 µm ( < .001) at 1 and 4 years of follow-up, respectively. BCVA improved from 0.28 ± 0.22 to 0.21 ± 0.48 (1 year, = .013) and 0.08 ± 0.13 logMAR (4 years, ). The proportion of patients requiring systemic corticosteroids decreased from 88.5% to 34.8% (1 year) and 15.4% (4 years).
Conclusion: The addition of a TNFi resulted in an improvement of CRT and BCVA for up to 4 years in uveitic ME but rescue treatments were needed for some patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09273948.2022.2075761 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!